AtriCure, Inc. (ATRC) is held by 1 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund adding versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $2.3M sold). 1 member of Congress reported 1 purchase vs 1 sale. Latest close $55.45 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 6, 2026 · Congress to Nov 16, 2026.
First Eagle Investment Management — 1 tracked fund hold ATRC. See all holders.
Insiders bought on the open market (0 purchases, $0) vs 7 sales ($2.3M). Insider trading 1 member of Congress reported buying (1 purchase vs 1 sale). Latest buy: Aug 20, 2026. Politician trading
BECTON DICKINSON & CO (BDX) · BOSTON SCIENTIFIC CORP (BSX) · BAXTER INTERNATIONAL INC (BAX) · STRYKER CORP (SYK) · Solventum Corp (SOLV) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| First Eagle Investment Management | 0.01% | 297,643 | ADDED (+13.5%) Q3 filed Nov 10 |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: +85.1% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 252 of 8,857 filers |
| Long-only filers among them | 250 |
| Change vs 2026 Q1 | +36 net · 243 entered · 207 exited |
| Shares reported, all filers | 52,218,733 |
| Reported value, all filers | $1.4B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | Surgical & Medical Instruments & Apparatus (SIC 3841) |
| Revenue · FY2025 | $534.5M |
| Net income · FY2025 | $-11.4M |
| Total assets · FY2025 | $654.2M |
| Shares outstanding | 50,866,294 |
| Market cap (at latest close) | $2.8B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 22, 2026.
| Shares short · Oct 15, 2026 | 4,886,394 |
| Share of shares outstanding | 9.61% |
| Days to cover | 5.21 |
Shares short at recent settlements — Jul 31, 2026: 3.9M · Aug 14, 2026: 3.9M · Aug 31, 2026: 4.1M · Sep 15, 2026: 4.3M · Sep 30, 2026: 4.8M · Oct 15, 2026: 4.9M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 22, 2026.
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 30 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 22, 2026.
0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 7 sales by 4 insiders ($2.3M).
Source: SEC Form 4 filings. Open-market transactions only.
Recent open-market trades
| Date | Insider | Role | Buy / Sell | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Nov 6, 2026 | JOHNSON B KRISTINE | Sell | 2,452 | $58.48 | $143.4K | SEC filing | |
| Nov 4, 2026 | Privitera Salvatore | Chief Technical Officer | Sell | 8,404 | $65.00 | $546.3K | SEC filing |
| Sep 23, 2026 | Privitera Salvatore | Chief Technical Officer | Sell | 4,519 | $60.00 | $271.1K | SEC filing |
| Sep 11, 2026 | GROVES REGINA E | Sell | 5,313 | $54.22 | $288.1K | SEC filing | |
| Sep 8, 2026 | Privitera Salvatore | Chief Technical Officer | Sell | 3,657 | $55.00 | $201.1K | SEC filing |
| Sep 2, 2026 | Privitera Salvatore | Chief Technical Officer | Sell | 7,763 | $52.50 | $407.6K | SEC filing |
| Aug 24, 2026 | Dahlquist Karl S. | Chief Legal Officer | Sell | 9,370 | $48.89 | $458.1K | SEC filing |
Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Sep 23, 2026 | SALVATORE PRIVITERA | Officer | 4,519 | $271.1K | Sep 23, 2026 | SEC filing |
| Sep 11, 2026 | GROVES REGINA E | Director | 5,313 | $285.1K | Sep 10, 2026 | SEC filing |
| Sep 8, 2026 | SALVATORE PRIVITERA | Officer | 3,657 | $201.1K | Sep 8, 2026 | SEC filing |
| Sep 2, 2026 | SALVATORE PRIVITERA | Officer | 7,763 | $407.6K | Sep 2, 2026 | SEC filing |
| Aug 24, 2026 | KARL DAHLQUIST | Officer | 9,370 | $458.1K | Aug 24, 2026 | SEC filing |
| Aug 5, 2026 | Prange Karen | Director | 3,564 | $139.0K | Aug 5, 2026 | SEC filing |
| Aug 5, 2026 | MAGGIE YUEN | Director | 3,500 | $134.5K | Aug 5, 2026 | SEC filing |
| Jul 29, 2026 | Noznesky Justin J | Officer | 6,182 | $239.9K | Jul 29, 2026 | SEC filing |
| Jul 28, 2026 | VINAYAK DORAISWAMY | Officer | 6,000 | $233.3K | Jul 28, 2026 | SEC filing |
| Jul 28, 2026 | SVEN WEHRWEIN | Director | 25,000 | $964.4K | Jul 28, 2026 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | AllianceBernstein L.P. | SC 13G/A | 2,768,365 | 5.5% | Jun 30, 2026 | SEC filing |
| May 15, 2026 | Wellington Management Group LLP | SC 13G/A | 3,382,555 | 6.8% | Mar 31, 2026 | SEC filing |
| Apr 29, 2026 | Vanguard Capital Management | SC 13G | 2,532,965 | 5.1% | Mar 31, 2026 | SEC filing |
| Apr 28, 2026 | Vanguard Portfolio Management | SC 13G | 2,744,685 | 5.5% | Mar 31, 2026 | SEC filing |
| Mar 26, 2026 | The Vanguard Group | SC 13G/A | 0 | 0.0% | Mar 13, 2026 | SEC filing |
| Feb 17, 2026 | Hood River Capital Management LLC | SC 13G/A | 3,096,611 | 6.2% | Dec 31, 2025 | SEC filing |
| Nov 13, 2025 | Macquarie Group Limited | SC 13G/A | 2,289,369 | 4.6% | Sep 30, 2025 | SEC filing |
| Oct 17, 2025 | BlackRock, Inc. | SC 13G/A | 3,862,837 | 7.8% | Sep 30, 2025 | SEC filing |
| Aug 12, 2025 | Macquarie Group Limited | SC 13G | 2,503,205 | 5.1% | Jun 30, 2025 | SEC filing |
| Aug 12, 2025 | Wellington Management Group LLP | SC 13G | 3,969,269 | 8.0% | Jun 30, 2025 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
1 member of Congress reported buying (1 purchase vs 1 sale). Bought by Democrats. Latest buy: Aug 20, 2026.
Source: U.S. House Clerk and U.S. Senate eFD STOCK Act periodic transaction reports, as of Nov 16, 2026. Reported amounts are ranges, and reports can arrive up to 45 days after the trade.
Recent activity by member
| Member | Chamber | Party | Buys | Sells | Latest | Amount range |
|---|---|---|---|---|---|---|
| Cisneros, Gilbert | House | D | 1 | 1 | Sep 29, 2026 | $1,001 - $15,000 |
Member-level activity in the current window, most recent first (House data to Nov 16, 2026, Senate to Oct 1, 2026). House reports arrive as PDFs without transaction-level rows in the current corpus, so this table shows per-member totals, not individual trades; the member page lists the underlying filings. Senate rows link the same way — the member page carries the eFD filing links.
Industry: Surgical & Medical Instruments & Apparatus (SIC 3841). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Lobbying: 28 Lobbying Disclosure Act filings named this company as client, 2021–2026; most common issues: Medicare/Medicaid (22), Copyright/Patent/Trademark (2).
Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).
Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.
Politicians
· Bought by Members — Last 6 months: bought by a member of the U.S. Congress
Financial Screens
· Growth — Revenue up every year for 5 straight years
· Gross Profitability (Novy-Marx) — High gross profit relative to total assets
Chart Signals
· Monthly Uptrend — Price above its 12-month moving average
· Top Relative Strength — Top 20% of the universe by 6-month return
Key figures
· Growth — Latest revenue: $534.5M · 5-yr revenue CAGR: 20.9% · Straight growth years: 5
· Gross Profitability (Novy-Marx) — Gross profit / assets: 61.3% · Gross margin: 75.0%
· Bought by Members — Members buying: 1 · Buy txns: 1 · Sell txns: 1 · Latest buy: Aug 20, 2026
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
Also held by the tracked funds that hold ATRC — ranked by lift, the co-holding pattern described in Methodology: BECTON DICKINSON & CO (BDX) · BOSTON SCIENTIFIC CORP (BSX) · BAXTER INTERNATIONAL INC (BAX) · STRYKER CORP (SYK) · Solventum Corp (SOLV) · Medline Inc. (MDLN) · 3M CO (MMM) · WEST PHARMACEUTICAL SERVICES INC (WST).
8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.
| Filed | Items | Source |
|---|---|---|
| Nov 3, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| Jul 23, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| May 19, 2026 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers · 5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
BECTON DICKINSON & CO (BDX) · Track Record: how the signals scored · Practice timing on ATRC
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.